Jafron Biomedical Co.,Ltd. Approves Profit Distribution for 2019; Approves Board Appointments
April 29, 2020 at 03:42 pm
Share
Jafron Biomedical Co.,Ltd. approved the profit distribution plan with the cash dividend (tax included) of CNY 9.00000000 per 10 shares in the annual general meeting held on April 28, 2020.
The company approved the election of Lei Wen, Zeng Kai and Li Feng as non-independent directors, election of Cui Songning, Zhou Linghong and Yang Bai as independent directors and Peng Xiaohong and Fang Lihua as non-employee supervisors of the company, at annual general meeting held on April 28, 2020.
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Companyâs products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Companyâs products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Companyâs products are applied in 31 provinces, more than 3000 hospitals in China.
JAFRON BIOMEDICAL CO.,LTD. 
